Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07162363 · ClinicalTrials.gov registry record · Phase 2
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT07162363: Clinical Trial Phase 2 study, sponsored by University of Illinois at Chicago.
NCT07162363 is a Phase 2 study that has not yet begun recruiting, run by University of Illinois at Chicago. The registered enrollment target is 240 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07162363, a Phase 2 study, has not yet begun recruiting, sponsored by University of Illinois at Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.
Primary Outcome
The Modified Rankin Scale (mRS) is a standard measure of global disability after stroke or intracerebral hemorrhage. For this study, a utility-weighted mRS (uw-mRS) will be used to account for patient-centered quality-of-life differences across mRS levels. Higher utility scores indicate better functional outcomes. The uw-mRS will be assessed at Days 30, 90, and 180 after randomization to evaluate the long-term impact of the intervention on patient functional recovery.
Interventions
- DRUG Deferoxamine
- PROCEDURE Minimally Invasive surgery (MIS)
- OTHER Standard Medical Care (SMD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
What is known before NCT07162363 opens enrollment
NCT07162363 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 3 interventions - of which Deferoxamine is the first listed.
NCT07162363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07162363 about?
NCT07162363 is a clinical study titled "Synergistic Minimally Invasive Surgery and Deferoxamine in ICH". This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This t...
What is the current status of trial NCT07162363?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-03-01. Estimated completion is 2028-12-30.
What interventions are being tested in trial NCT07162363?
The interventions under investigation include: Deferoxamine (DRUG), Minimally Invasive surgery (MIS) (PROCEDURE), Standard Medical Care (SMD) (OTHER).
Who is sponsoring clinical trial NCT07162363?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07162363's enrollment target sits among peer trials
240 239th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI